Iomab-B Makes Actinium Pharma A Rare And Exciting Investment Opportunity

(Click on image to enlarge)


This is where Iomab-B has the real potential to change the market because Iomab-B is an induction and conditioning agent at the same time. Induction is killing leukemic cells and conditioning is ablating bone marrow. This is traditionally done in sequential steps with different chemotherapeutic agents. By targeting CD45, a protein found on the surface normal bone marrow cells and up to 90% of leukemia cells, Iomab-B wipes out both leukemia and bone marrow in one single infusion through high-range, low-energy radiation. However, because CD45 is not expressed on any other cell types, Iomab-B has excellent systemic tolerability and can be used in elderly patients with co-morbidities and on unrelated medications.
 

(Click on image to enlarge)

Another important differentiator is the speed at which Iomab-B works. For example, the time to BMT for traditional salvage chemotherapy is a minimum of 28-42 days. As noted above, induction and conditioning are done in sequential steps. Toxicities are high and there is a significant risk of serious adverse events. Complete remission rates are low, ranging between 25-35%. However, with Iomab-B, the therapeutic dose is administered via a single infusion. Time to BMT is only 12 days and previous clinical studies suggest good safety and tolerability.
 

(Click on image to enlarge)


The result is significantly higher complete remission rates vs. salvage chemotherapy. In fact, results of the previous Phase 1/2 clinical study show 100% of patients on Iomab-B achieved complete remission (CR) and 100% went on to receive a BMT. More importantly, this resulted in an increase in overall survival for patients taking Iomab-B versus historical survival rates of patients treated with standard chemotherapy using data from Fred Hutchinson and MD Anderson (see below).

 

(Click on image to enlarge)


KOL's Taking Notice

In February 2017, Actinium attended the combined meeting of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT), commonly referred to as "BMT Tandem". It is important to note that several clinical investigators and key opinion leaders in the AML space are starting to talk about the potential for Iomab-B.

For example, Dr. Jeffrey Lancet, MD of the Moffitt Cancer Center presented results from Celator's Phase 3 trial with Vyxeos. Dr. Lancet was a principal investigator in that trial. The picture below shows Dr. Lancet discussing Iomab-B and the Phase 3 SIERRA trial being conducted by Actinium as a means to deliver a more effective antileukemic therapy to the bone marrow without inducing too much toxicity. Dr. Lancet noted that Iomab-B has the potential to bring in a new population of patients who traditionally would not be considered for a transplant because they have active disease.
 


Another prominent KOL that noted Iomab-B during their talk was Dr. Sergio Giralt, Chief of Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center (MSK). During this talk, Dr. Giralt spoke about a void in the market for elderly patients that are not candidates for standard transplant. He went on to highlight previous data from Iomab-B noting, "I think we would agree that for patients with active disease, these are very good results." The website OncLive posted an article after interviewing Dr. Giralt talking about the previous Iomab-B data.
 

View single page >> |

Disclaimer: BioNap is NOT an Investment Advisor. We are an investor intelligence and strategic advisory firm. Most of the companies mentioned on this blog are party to a services ...

more
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.